top of page

NICE says Bayer’s liver cancer drug is not cost-effective

The National Institute for Health and Care Excellence (NICE) has released draft guidance that liver cancer drug sorafenib (Nexavar, Bayer) – which is currently available on the Cancer Drugs Fund (CDF) – is not value for money.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page